References
Every guideline, study and public source cited on this website, in one place.
Cited sources
- Alzheimer's Association. 2026 Alzheimer's Disease Facts and Figures. Chicago: Alzheimer's Association; 2026. View source (opens in a new tab)
- Alzheimer's Association. 10 early signs and symptoms of Alzheimer's and dementia. View source (opens in a new tab)
- Alzheimer's Association. Mild cognitive impairment (MCI). View source (opens in a new tab)
- National Institute on Aging. Alzheimer's disease fact sheet. Updated April 5, 2023. View source (opens in a new tab)
- Dickerson BC, Atri A, Clevenger C, et al. The Alzheimer's Association clinical practice guideline for the Diagnostic Evaluation, Testing, Counseling, and Disclosure of Suspected Alzheimer's Disease and Related Disorders (DETeCD-ADRD): executive summary of recommendations for specialty care. Alzheimers Dement. 2025;21(1):e14337. View source (opens in a new tab)
- Palmqvist S, Whitson HE, Allen LA, et al. Alzheimer's Association clinical practice guideline on the use of blood-based biomarkers in the diagnostic workup of suspected Alzheimer's disease within specialized care settings. Alzheimers Dement. 2025;21(7):e70535. View source (opens in a new tab)
- NeurologyLive. FDA clears Roche's single-biomarker Elecsys pTau217 blood test for Alzheimer disease. August 24, 2026. View source (opens in a new tab)
- US Preventive Services Task Force. Cognitive impairment in older adults: screening. Final recommendation statement, February 25, 2020 (update in progress). View source (opens in a new tab)
- Livingston G, Huntley J, Liu KY, et al. Dementia prevention, intervention, and care: 2024 report of the Lancet standing Commission. Lancet. 2024;404(10452):572-628. View source (opens in a new tab)
- Baker LD, Espeland MA, Whitmer RA, et al. Structured vs self-guided multidomain lifestyle interventions for global cognitive function: the US POINTER randomized clinical trial. JAMA. 2025;334(8):681-691. View source (opens in a new tab)
- Barnes LL, Dhana K, Liu X, et al. Trial of the MIND diet for prevention of cognitive decline in older persons. N Engl J Med. 2023;389(7):602-611. View source (opens in a new tab)
- Aggarwal NT, Mielke MM. Sex differences in Alzheimer's disease. Neurol Clin. 2023;41(2):343-358. View source (opens in a new tab)
- American Heart Association. Life's Essential 8. View source (opens in a new tab)
- U.S. Food and Drug Administration. FDA approves treatment for adults with Alzheimer's disease (Kisunla, donanemab-azbt). July 2, 2024. View source (opens in a new tab)
- NeurologyLive. FDA approves updated label for donanemab with modified titration to lower ARIA-E risk. July 2025. View source (opens in a new tab)
- Alzheimer's Association. Alzheimer's Association welcomes FDA approval of Leqembi subcutaneous starter dose. July 13, 2026. View source (opens in a new tab)
- Cummings J, Apostolova L, Rabinovici GD, et al. Lecanemab: appropriate use recommendations. J Prev Alzheimers Dis. 2023;10(3):362-377. View source (opens in a new tab)
- Rabinovici GD, Selkoe DJ, Schindler SE, et al. Donanemab: appropriate use recommendations. J Prev Alzheimers Dis. 2025;12(5):100150. View source (opens in a new tab)
- Nonino F, Minozzi S, Sambati L, et al. Amyloid-beta-targeting monoclonal antibodies for people with mild cognitive impairment or mild dementia due to Alzheimer's disease. Cochrane Database Syst Rev. 2026;(4):CD016297. View source (opens in a new tab)
- The Pharmaceutical Journal. Amyloid-targeting Alzheimer's drugs 'probably' not effective, review finds (with expert responses). April 16, 2026. View source (opens in a new tab)
- National Institutes of Health. NIH Clinical Research Trials and You. View source (opens in a new tab)
- National Institute on Aging. Clinical trials and studies. View source (opens in a new tab)
- U.S. National Library of Medicine. ClinicalTrials.gov. View source (opens in a new tab)
- Alzheimer's Association. TrialMatch: find Alzheimer's and dementia clinical studies. View source (opens in a new tab)
Links point to the publishing organization or the article's permanent DOI. Guidance changes; always check for the most recent version.